


Long non-coding RNA panel to better characterize patients with cardiac disorders and toxicities



Product Overview

FiMICS is the result of years of research on cardiac lncRNAs in cooperation with several research institutes of excellence and the collaboration with Celemics, a Seoul based biotech company specialized in Next-Generation Sequencing solutions. lncRNAs are a highly tissue specific family of RNA opening new horizons for diagnostic and therapeutic applications in the cardiovascular field. Identification of cardiac enriched lncRNAs were performed using deep sequencing human cardiac biopsies of failing and control hearts. Expression levels were compared to 12 others organs to select cardiac enriched lncRNAs. A total of 3233 lncRNAs including 1036 novel lncRNAs never previously described were identified and included into FiMICS panel. Detection and precise quantification of these **cardiac enriched lncRNAs in peripheral blood** using FiMICS provide first-class results to the final users and opens new ways for therapeutics and precision medicine tools for diverse primary and secondary cardiac diseases, cardiac toxicities and drug development.

Features & Benefits

- ▮ First in class test for the measurement of cardiac enriched lncRNA in peripheral blood
- ▮ Proprietary list of cardiac enriched lncRNAs coming from years of research
- ▮ More than 55.000 capture probes for high coverage of lncRNAs sequences
- ▮ Investigation of a novel class of biomarkers/therapeutic targets
- ▮ Get direct insight of heart condition using blood without needing cardiac biopsies.
- ▮ Characterization of patients with diverse cardiac disorders and toxicities



Contact us to start your pilot study

sales@firalis.com


High detection rate of cardiac enriched lncRNAs in peripheral blood



Precaution: Research Use Only kit, not designed for diagnosis and / or therapeutics procedures

FiMICS panel now available



Long non-coding RNA panel to better characterize patients with cardiac disorders and toxicities



FiMICS IncRNAs analysis workflow: from sample to results

Firalis' expertise

- Non-invasive samples to investigate cardiac enriched IncRNAs
- PAXgene and cardiac tissue already validated.
- Excellent analytical performance with high reproducibility of the results
- High sensitivity with ~2800 IncRNAs detected in PAXgene samples over 3233 (FPKM>0,1)
- **Plasma samples** in validation process with more than 1500 IncRNAs detected (FPKM>0,1)



Learn More

Firalis is a biotechnology company with a mission to improve disease outcome, therapeutic decisions and generate savings in healthcare through biomarker discovery, development and regulatory qualification that ultimately leads to biomarker-based diagnostics. Firalis develops and markets RUO and IVD kits in the field of cardiovascular, neurodegenerative, inflammatory and autoimmune diseases developed in a cutting-edge laboratory in a very high-quality environment (ISO 9001, ISO 13485, ISO 17025 and NF S 96-900).

Partners

